Introduction
============

Schizophrenia is one of the most common psychotic disorders. The 1-month prevalence of schizophrenia in the mainland Chinese population is 0.78% according to an epidemiologic study conducted in four provinces.[@b1-ndt-12-113] Antipsychotics have been the mainstay of treatment for schizophrenia.

Paliperidone, also referred to as 9-hydroxyrisperidone, is the major active metabolite of risperidone.[@b2-ndt-12-113] The mechanism of action of paliperidone is unknown; however, it is known that it acts as an antagonist at dopamine-2 (D~2~) receptors and 5-hydroxytryptamine 2A (5-HT~2A~) receptors, with a higher affinity for 5-HT~2A~ receptors than for D~2~ receptors. In addition, paliperidone also acts as an antagonist at α~1~-adrenoceptors, and binds with lower affinity to α~2~-adrenoceptors and histamine-1 receptors. It has no affinity for cholinergic muscarinic receptors.[@b3-ndt-12-113] Paliperidone is available as two extended-release (ER) formulations: an osmotic-controlled-release oral delivery system (Paliperidone ER, Invega), and an injectable suspension formulation of paliperidone palmitate (PP, Sustenna^®^). Paliperidone ER utilizes osmotic-controlled-release oral delivery system (OROS^®^) technology to provide sustained release over a 24-hour period, thereby reducing fluctuations in peak and trough plasma concentrations.[@b4-ndt-12-113] It is administered once daily without initial dose titration, and was introduced in the People's Republic of China in 2009 for the treatment of schizophrenia. PP is the first monthly long-acting injectable atypical antipsychotic agent in the People's Republic of China.[@b5-ndt-12-113] It was marketed in 2012, also indicated for schizophrenia. At present, these two formulations of paliperidone are in wide use in clinical practice in the People's Republic of China.

There have been some studies evaluating the pharmacokinetic characteristics and clinical profiles of both paliperidone formulations in the Chinese population. The aim of our systematic review is to summarize the clinical evidence of the pharmacokinetic characteristics, efficacy, effectiveness, and safety of paliperidone in treating schizophrenia in the People's Republic of China.

Methods
=======

Data search
-----------

PubMed, Embase, and Cochrane Library databases and the Cochrane Controlled Trials Register of paliperidone ER or PP for schizophrenia in Chinese population were searched, as well as Chinese databases of China National Knowledge Infrastructure (CNKI) (<http://www.cnki.net>), Wanfang data (<http://www.wanfangdata.com.cn>) and CBM/VIP information (<http://www.cqvip.com>). The search included all clinical studies published between January 1, 2008, and May 22, 2015 (search date), supplemented by hand search of academic dissertations and several key literature sources. The search was conducted using several types of key terms, categories of country or region, disease classification, and treatment. For the category of country or region, the key terms were "China", "Chinese", "Taiwan", "Taiwanese", and "Hong Kong". For the category of disease classification, the search term was "schizophrenia". For the category of treatment, the key terms were "paliperidone", "9-OH risperidone", "Invega", and "Sustenna". For all the databases, search terms within each category were combined by using the Boolean operator OR. Categories were then combined by using the Boolean operator AND.

Study selection
---------------

Chinese language studies included in this review were restricted to the Chinese core medical journals, based on the Guide of Core Journal of China (2011 version) published by Peking University Press.[@b6-ndt-12-113] The study participants were residents of the People's Republic of China, Taiwan, or Hong Kong, with a diagnosis of schizophrenia by any criteria, irrespective of age or sex. The types of intervention were paliperidone ER or PP. The included studies also had to report numerical data on at least one recognized outcome measure related to efficacy, effectiveness, or safety/tolerability. Studies were excluded if they were duplicate publications, or had no numerically reportable data on at least one relevant outcome measure. Case reports, narrative reviews, editorials, letters to the editor, or publications that did not include any formulation of paliperidone as the intervention were also excluded.

Results
=======

Results of the search
---------------------

A total of 122 publications were retrieved from the literature databases ([Figure 1](#f1-ndt-12-113){ref-type="fig"}). Sixty of these were excluded because they did not meet the criteria of study selection. In addition, a publication about the pharmacokinetics of paliperidone ER conducted in healthy Chinese subjects, which was omitted in the initial electronic search, was added manually. A total of 63 publications were finally included in the review. Detailed information of the 63 publications are cited in Supplementary material.

Characteristics of the studies
------------------------------

Among the 63 publications included in the review, 53 were related to paliperidone ER, nine were related to PP, and one study compared paliperidone ER and PP. Most paliperidone ER-related publications were interventional studies, including 34 randomized controlled trials (RCTs) and 17 open-label, single-arm studies. Of the two nonintervention studies, one was observational, and the other a pharmacokinetic study. Of the nine PP-related studies, four were RCTs, three were observational studies, and two studies assessed the pharmacokinetics of PP in patients with schizophrenia.

These publications were published in either international peer-reviewed journals (publications in English, n=15) or Chinese core journals (publications in Chinese, n=48).

Paliperidone ER
---------------

### Pharmacokinetic characteristics

Only one study had been performed to assess the pharmacokinetics of paliperidone ER in healthy Chinese subjects.[@b7-ndt-12-113] This was a single-center, double-blind, randomized, single-dose study. A total of 24 healthy Han Chinese subjects (13 men, eleven women), aged 19--35 years, were randomly assigned in a 1:1 ratio to receive either paliperidone ER 3 or 9 mg. Mean *t*~max~ and *t*~1/2~ were 22.2 and 22.8 hours for the 3 mg group, and 24.8 and 21.4 hours for the 9 mg group. Similar to the pharmacokinetic data reported for the Caucasian population, the pharmacokinetics of paliperidone ER in the Chinese population can be adequately described by a one-compartment pharmacokinetic model, and is linearly related to dose. Based on these data, paliperidone ER is suitable to be taken once daily in the morning.

### Efficacy outcomes

The efficacy of paliperidone ER in Chinese patients was assessed in 35 comparative studies ([Table 1](#t1-ndt-12-113){ref-type="table"}) and 17 single-arm studies. All the drugs used for comparison were atypical oral antipsychotics, mostly risperidone (n=13) and olanzapine (n=9), followed by aripiprazole (n=3), ziprasidone (n=2), and clozapine (n=2).

The mean change in Positive and Negative Syndrome Scale (PANSS) total scores compared with baseline was the most commonly reported symptom outcome. The overall findings from comparative studies and single-arm studies were consistent: paliperidone ER treatment was associated with statistically significant reductions in PANSS total scores. The median change in PANSS total score was −38.60 in RCTs, and −34.48 in single-arm studies. In almost two-third of RCTs (21/33), the relative reduction in PANSS total score at the end point was \>40%. Response rate was also a commonly used item to identify symptom outcome, but the definitions were different, and it was difficult to unify the definition of response.

Most of these studies were short-term studies, with duration of 4--12 weeks. Only three studies evaluated the long-term efficacy and safety of paliperidone ER: the duration of one study was 6 months, and that of the other two was 1 year.[@b8-ndt-12-113]--[@b10-ndt-12-113] The results were consistent with other international data. Paliperidone ER was efficacious in the long term and significantly delayed relapse in Chinese patients with schizophrenia. No new safety signals were detected.

### Onset of action

Consistent results reported that paliperidone ER has a much more rapid onset of action than risperidone or olanzapine in the first week ([Table 2](#t2-ndt-12-113){ref-type="table"}). Eight RCTs presented PANSS or Brief Psychiatric Rating Scale (BPRS) total score data in week 1; three of these compared the data for paliperidone ER with that for risperidone, and five compared the data for paliperidone ER with that for olanzapine. In all these eight studies, paliperidone ER effected significant reduction in PANSS total score at week 1 compared with that at baseline. The paliperidone ER group achieved lower PANSS or BPRS total score at week 1 in all studies compared with risperidone (3/3, *P*\<0.05), and in most studies compared with olanzapine (3/5, *P*\<0.05). Paliperidone ER treatment also resulted in significantly lower PANSS or BPRS total scores compared with risperidone in week 2; however, the results were comparable with those for olanzapine. There was not enough information to determine the dose details in week 1 and week 2, but the OROS^®^ technology of paliperidone ER allowed initiation with effective dosage, which could benefit the onset.

### Effectiveness outcomes

Seventeen comparative studies and 12 single-arm studies reported effectiveness outcomes, including functionality, neurocognitive function, and quality of life. The most commonly used effectiveness assessment was the Personal and Social Performance Scale (PSP) to assess functionality. Eleven comparative studies and ten single-arm studies reported PSP outcome. Paliperidone ER treatment significantly improved the PSP score at the end point compared with that at baseline in all these studies ([Table 3](#t3-ndt-12-113){ref-type="table"}). In all eleven comparative studies, paliperidone ER resulted in significantly better PSP scores at the end point than those achieved with comparative drugs, including risperidone, olanzapine, and aripiprazole.

Three comparative studies and three single-arm studies reported neurocognitive function outcome,[@b11-ndt-12-113]--[@b16-ndt-12-113] assessed by different tools including the Wisconsin Card Sorting Test, Wechsler Memory Scale-Revised, Stroop, or Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative -- Consensus Cognitive Battery. Neurocognitive outcome was the primary outcome in one comparative study and three single-arm studies. In all these studies, paliperidone ER treatment significantly improved neurocognitive function at the end point compared with that at baseline.

Quality of life was assessed in four trials,[@b12-ndt-12-113],[@b17-ndt-12-113]--[@b19-ndt-12-113] using different tools including the Short Form-36 Health Survey, The World Health Organization Quality of Life 100, Social Disability Screening Schedule, and Overall Quality of Life Rating Scale. In all these studies, paliperidone ER treatment significantly improved the quality of life at the end point compared with that at baseline.

### Safety and tolerability

Safety and tolerability outcome was reported in most studies. The most commonly reported treatment-emergent adverse events (TEAEs) were extrapyramidal symptoms (EPSs), insomnia or somnolence, and prolactin-related TEAEs. Paliperidone ER was generally well tolerated in the Chinese population, and no special safety signal was found.

### Extrapyramidal symptoms

EPSs were the most frequently reported TEAE reported in these articles as EPS, akathisia, dyskinesia, tumor, dystonia, and Parkinsonism. The incidence of EPSs associated with paliperidone ER treatment was lower than that with risperidone treatment but higher than that with olanzapine treatment.

### Prolactin elevation

Six RCTs and three single-arm studies tested plasma prolactin level; the study duration ranged from 4 to 12 weeks. Paliperidone ER significantly increased plasma prolactin level compared with that at baseline. The prolactin level in the paliperidone ER group was significantly lower than that in the risperidone group but higher than that in the olanzapine and aripiprazole groups. The potential prolactin-related TEAEs were not especially reported in most studies. In five studies that reported potential prolactin-related TEAEs, including irregular menstruation, amenorrhea, galactorrhea, and gynecomastia, the total incidence was 0%--5%.[@b17-ndt-12-113],[@b20-ndt-12-113]--[@b23-ndt-12-113]

### Weight and metabolic parameters

Eight RCTs and four single-arm studies reported outcomes related to weight gain and metabolic parameters. Most of the studies had a duration of 6--12 weeks, except a 52-week study. The most commonly assessed metabolic parameters were levels of glucose and lipids in plasma. In the 6- to 12-week studies, paliperidone ER treatment resulted in an insignificant change or significant but mild change in mean weight. Paliperidone ER treatment caused no significant change in blood glucose levels. In most studies, paliperidone ER treatment caused no significant change in lipid metabolism, although some studies showed a small increase in triglyceride levels. Generally, in these short-duration studies, paliperidone ER was well tolerated in terms of effect on weight and metabolic parameters, and had some advantage over olanzapine in terms of weight gain, and glucose and lipid metabolism.[@b21-ndt-12-113],[@b22-ndt-12-113],[@b24-ndt-12-113]

Paliperidone palmitate
----------------------

PP-related studies in the Chinese population included two pharmacokinetic studies, four comparative studies, and three single-arm studies.

Among the pharmacokinetic studies, the first one was an open-label, randomized, parallel-group, multicenter study in patients with chronic schizophrenia.[@b25-ndt-12-113] On day 1, 48 eligible subjects were randomly assigned in a 1:1:1 ratio to 25, 100, or 150 mg PP groups; the same dose as that assigned on day 1 was injected on day 8 on the other side of the gluteal muscle. The plasma concentrations of paliperidone gradually increased to a *C*~max~ at a mean *t*~max~ of 13 days. The area under the curve (AUC) (0--35 days), AUC (0--210 days), and AUC (0--∞) for the three doses were dose-proportional. The median half-life (*t*~1/2~) ranged from 42 to 77 days, and the *t*~1/2~ was prolonged for higher doses. The therapeutic regimen for PP in this study was different from the recommended regimen. The second study was designed to evaluate the pharmacokinetics of PP after multiple doses (the recommended dosing regimen): 150 mg on day 1, followed by 100 mg on day 8.[@b26-ndt-12-113] Thereafter, a flexible dose (75, 100, or 150 mg) was administered monthly, based on the patient's response, consecutively for 6 months. The mean *C*~max~ was 17--25 ng/mL at a mean *t*~max~ of 11--17 days. Based on these data, the pharmacokinetic characteristics of PP in the Chinese population were similar to those found in studies on the Caucasian population.[@b27-ndt-12-113],[@b28-ndt-12-113]

The first comparative study was a registration study of PP for its introduction to the Chinese market.[@b29-ndt-12-113] It was a noninferiority-design, open-label, rater-blinded, parallel-group, 13-week study. The active comparator was risperidone long-acting injectable (RIS-LAI, 25--50 mg/2 weeks). A significant improvement with respect to baseline was observed at the end point for both groups; mean (standard deviation) change from baseline to end point in PANSS total scores was −23.6 (16.28) for the PP group and −26.9 (15.43) for the RIS-LAI group. The mean change in PSP was 16.8 (PP group) and 18.6 (RIS-LAI group), and the overall incidence of TEAEs was not different between the groups.

Three subsequent small sample size, open-label, randomized, comparative studies of PP and oral risperidone were conducted with the recommended initiation dosing regimen for PP over durations of 6, 8, and 12 weeks.[@b30-ndt-12-113]--[@b32-ndt-12-113] The mean change from baseline to end point in PANSS total score and the tolerability were comparable between both groups. A total of three single-arm studies of PP was conducted to establish the effects of PP on acute or recent-onset patient hospitalization rates.[@b33-ndt-12-113]--[@b35-ndt-12-113] The results showed that PP treatment significantly (*P*\<0.0001) reduced both the number of hospitalizations and the number of days spent in the hospital. The most frequently reported TEAEs were injection-site pain, EPSs, akathisia, and insomnia.

Discussion
==========

This study was a systematic review carried out to critically evaluate the efficacy, effectiveness, and safety of paliperidone (as the oral ER and 1-month long-acting injection formulations) in the Chinese population. The results demonstrated that the efficacy of paliperidone ER was at least comparable with that of other atypical antipsychotics, which was consistent with the results of the latest meta-analysis of Chinese patients with schizophrenia.[@b36-ndt-12-113] The onset of symptom control was faster in the paliperidone ER group, compared with the risperidone group at week 1 and week 2, and the olanzapine treatment at week 1. This may be because the OROS^®^ technology and pharmacokinetic profile of paliperidone ER allow once-daily dosing with an initial dose of 6 mg and no need for initial dose titration, which enables rapid action. A review summarized the time required to achieve significant alleviation of psychiatric symptoms compared with baseline;[@b37-ndt-12-113] paliperidone ER and risperidone showed alleviation of symptoms from day 4, while olanzapine, aripiprazole, and ziprasidone took 1--2 weeks. However, there were no available head-to-head comparison results. Our findings could help to enrich the data on antipsychotic onset of action. Paliperidone was well tolerated in the Chinese population, and no special safety issues were found. The incidence of EPSs and increase in prolactin levels associated with paliperidone ER treatment were lower than that with risperidone treatment but higher than that with olanzapine treatment. This was consistent with the result of other studies.

Paliperidone ER treatment resulted in a significantly better PSP score at the end point compared with other antipsychotics including risperidone, olanzapine, and aripiprazole. This was a novel finding of our systematic review. There are a limited number of randomized controlled studies comparing paliperidone ER and other antipsychotics in international publications. No RCTs have compared the functionality outcome between paliperidone ER and risperidone or aripiprazole. Three 6-week studies identified the efficacy and safety of paliperidone ER, and used olanzapine 10 mg/d treatment to confirm trial validity; the pooled data showed that there was no significant difference in mean PSP score change from baseline to end point between paliperidone ER and olanzapine groups. A period of 6 weeks may not be enough to test the functionality outcome, as it is influenced by several factors, including not only positive symptoms but also negative symptoms, affective symptoms, cognitive symptoms, and side effects such as sedation and metabolic syndrome.[@b38-ndt-12-113]--[@b42-ndt-12-113] The efficacy of paliperidone ER is at least comparable to that of other antipsychotics, and it has a better safety profile than risperidone, and less severe sedative and metabolic effects than olanzapine. This might be the reason for the better functionality outcome of paliperidone ER treatment found in our review. However, the sample size of studies included in this systematic review is relatively small, and PSP is not the primary end point in most studies, so the effectiveness of antipsychotics in functionality improvement still needs further verification in the future. Results from studies on PP demonstrated that it is an effective and well-tolerated treatment for Chinese patients with schizophrenia, and may have some advantage in terms of functionality and patient's medication satisfaction compared with the oral formulation. Additionally, several studies have demonstrated that LAI has an advantage over oral antipsychotics in preventing relapse, and in reducing hospitalization rate and number of hospitalization days.[@b34-ndt-12-113],[@b43-ndt-12-113],[@b44-ndt-12-113] The studies on PP were fewer than those on paliperidone ER; a People's Republic of China international survey in 2012 showed that only 2.75% of patients with schizophrenia use LAI antipsychotics, and only 0.48% use atypical LAIs.[@b45-ndt-12-113] Both LAI data on clinical research and LAI usage in clinical practice need to be improved in the People's Republic of China.

There were some problems related to study quality, especially with publications from Chinese core journals. Most of the RCTs from Chinese core journals in this review did not clearly elucidate the methods of randomization, or information about blinding. Some studies did not give detailed information about mean dose, which caused difficulty in comparing between different treatment arms. The duration of most studies was 6--12 weeks; long-term studies were relatively fewer. Additionally, the sample sizes of some studies were relatively small.

Conclusion
==========

Paliperidone is one of the first-line antipsychotics used in the People's Republic of China. Both paliperidone ER and PP are effective, safe, and well tolerated in Chinese patients with schizophrenia according to the data we reviewed. Paliperidone may have some advantage over other antipsychotics in terms of onset of action and functionality improvement. Future studies could focus more on long-term data and LAI treatment.

Supplementary material
======================

###### 

Overview of study characteristics

  Study                                                                               Type   Study design                        Blind   Primary sources of potential bias                                          Patient profile             Age overall or group means[\*](#tfn20-ndt-12-113){ref-type="table-fn"}   Sex (% male)   Outcome                                  Primary outcome measures    Available outcome measures
  ----------------------------------------------------------------------------------- ------ ----------------------------------- ------- -------------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------------ -------------- ---------------------------------------- --------------------------- -----------------------------------------------------------------------------------
  **Paliperidone ER**                                                                                                                                                                                                                                                                                                                                                                                        
  Paliperidone ER compared with risperidone                                                                                                                                                                                                                                                                                                                                                                  
   Liu et al[@b86-ndt-12-113]                                                         CC     RCT                                 OL      Observer expectation                                                       First-episode               31.24, 32.04                                                             54.0           Efficacy, effectiveness                  PANSS                       PANSS, WCST, CPT, CT, WMS-R
   Li et al[@b92-ndt-12-113]                                                          CC     RCT                                 NR      Blinding, noncompleters excluded                                                                       20--59                                                                                  Efficacy, effectiveness, safety          PANSS                       PANSS, ESRS, SF36, PSP, metabolic measures, prolactin, adverse events
   Su et al[@b121-ndt-12-113]                                                         CC     RCT                                 OL      Observer expectation                                                                                   34.7, 35.4                                                               48.9           Efficacy, effectiveness, safety          PANSS, PSP                  PANSS, PSP, MSQ, adverse events
   Ren et al[@b122-ndt-12-113]                                                        CC     RCT                                 NR      Blinding                                                                                               30.4, 31.2                                                               63.2           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, adverse events
   Zhou et al[@b123-ndt-12-113]                                                       CC     RCT                                 NR      Blinding, noncompleters excluded                                           First-episode               27.6, 26.9                                                               47.2           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, adverse events
   Na et al[@b95-ndt-12-113]                                                          CC     RCT                                 OL      Observer expectation                                                                                   33.7, 34.5                                                               48.8           Efficacy, safety                         PANSS                       PANSS, prolactin, metabolic measures, TESS
   Li et al[@b124-ndt-12-113]                                                         CC     RCT                                 NR      Blinding                                                                   Adolescent                  16.61                                                                    41.2           Efficacy, effectiveness, safety          PANSS                       PANSS, TESS, laboratory examination, PSP
   Zhang et al[@b125-ndt-12-113]                                                      CC     RCT                                 NR      Blinding, noncompleters excluded                                                                       32, 33                                                                   46.2           Efficacy, safety                         PANSS                       PANSS, TESS
   Yuan et al[@b126-ndt-12-113]                                                       CC     RCT                                 NR      Blinding, noncompleters excluded                                                                       33.1, 34.5                                                               56.5           Efficacy, effectiveness                  PANSS                       PANSS, CGI, PSP
   Li et al[@b127-ndt-12-113]                                                         CC     RCT                                 OL      Observer expectation, noncompleters excluded                               First-episode, male         28.6, 27.9                                                               100.0          Efficacy, safety                         PANSS, metabolic measures   PANSS, metabolic measures
   Deng et al[@b128-ndt-12-113]                                                       CC     RCT                                 OL      Observer expectation                                                       First-episode, female       27.08, 26.00                                                             0.0            Efficacy, safety                         BPRS                        BPRS, TESS
   Liu et al[@b129-ndt-12-113]                                                        CC     RCT                                 DB                                                                                 First-episode               29, 30                                                                   53.3           Efficacy, safety                         PANSS                       PANSS, TESS, metabolic measures, prolactin
   Wang et al[@b93-ndt-12-113]                                                        CC     RCT                                 OL      Observer expectation                                                                                   35, 37                                                                   45.7           Efficacy, effectiveness, safety          PANSS                       PANSS, SDSS, TESS
  Paliperidone ER compared with olanzapine                                                                                                                                                                                                                                                                                                                                                                   
   Hu et al[@b96-ndt-12-113]                                                          Int    RCT                                 OL      Observer expectation, noncompleters excluded                                                           25.24, 28.65                                                             69.1           Efficacy, safety                         PANSS, metabolic measures   PANSS, metabolic measures, adverse events, prolactin
   Zhu et al[@b99-ndt-12-113]                                                         CC     RCT                                 NR      Blinding                                                                   Refractory                  42.7, 43.5                                                                              Efficacy, safety                         PANSS                       PANSS, TESS, metabolic measures
   Xie et al[@b131-ndt-12-113]                                                        CC     RCT                                 OL      Observer expectation, noncompleters excluded                               First-episode, adolescent   13.5, 14.6                                                               50.7           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, TESS, laboratory examination
   Ma et al[@b132-ndt-12-113]                                                         CC     RCT                                 NR      Blinding                                                                                               38.6, 39.4                                                               53.2           Efficacy, safety                         BPRS                        BPRS, TESS
   Cao et al[@b133-ndt-12-113]                                                        CC     RCT                                 NR      Blinding                                                                                               26.00, 27.12                                                             53.2           Efficacy, safety                         PANSS                       PANSS, TESS
   Su et al[@b134-ndt-12-113]                                                         CC     RCT                                 NR      Blinding                                                                                               31.0, 32.0                                                               51.5           Efficacy, safety                         BPRS                        BPRS, SAPS, TESS
   Liang[@b135-ndt-12-113]                                                            CC     RCT                                 OL      Observer expectation, noncompleters excluded                                                           30.42, 29.47                                                             53.9           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, TESS
   Guo et al[@b136-ndt-12-113]                                                        CC     RCT                                 NR      Blinding                                                                                               35.8, 33.6                                                               68.3           Efficacy, safety                         Liver function              Liver function, PANSS, TESS
   Zhang et al[@b97-ndt-12-113]                                                       CC     RCT                                 DB                                                                                                             33, 34                                                                   54.2           Efficacy, safety                         PANSS                       PANSS, CGI-S, adverse events, metabolic measures, VAS, AIMS, BARS, SAS, prolactin
  Paliperidone ER compared with aripiprazole                                                                                                                                                                                                                                                                                                                                                                 
   Zhang et al[@b84-ndt-12-113]                                                       Int    RCT                                 OL      Observer expectation, noncompleters excluded                               First-episode               27.1, 25.7, 26.3                                                         38.9           Efficacy, safety                         PANSS, metabolic measures   PANSS, CGI-S, metabolic measures
   Xie et al[@b137-ndt-12-113]                                                        CC     RCT                                 NR      Blinding, noncompleters excluded                                           First-episode, adolescent   14, 15                                                                   52.4           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, TESS
   Zhou et al[@b138-ndt-12-113]                                                       CC     RCT                                 NR      Blinding                                                                   Male                        35.8, 35.5                                                               100.0          Efficacy, effectiveness, safety          PANSS, sexual function      PANSS, PSP, sexual function, prolactin
  Paliperidone ER compared with clozapine                                                                                                                                                                                                                                                                                                                                                                    
   Luo et al[@b87-ndt-12-113]                                                         CC     RCT                                 NR      Blinding                                                                                               33.4, 32.9                                                               51.7           Efficacy, effectiveness, safety          PANSS                       PANSS, TESS, WHOQOL·100, SDSS, WMS-R
   Liu et al^64^                                                                      CC     RCT                                 OL      Observer expectation                                                       Refractory                  41.46, 39.84                                                             58.0           Efficacy, safety                         PANSS                       PANSS, TESS
  Paliperidone ER compared with ziprasidone                                                                                                                                                                                                                                                                                                                                                                  
   Zhang et al[@b84-ndt-12-113]                                                       Int    RCT                                 OL      Observer expectation, noncompleters excluded                               First-episode               27.1, 25.7, 26.3                                                         38.9           Efficacy, safety                         PANSS, metabolic measures   PANSS, CGI-S, metabolic measures
   He et al[@b94-ndt-12-113]                                                          CC     RCT                                 DB      Noncompleters excluded                                                                                 33.4, 32.8                                                               52.9           Efficacy, effectiveness, safety          GQOLI-74                    GQOLI-74, PANSS, TESS
  Paliperidone ER compared with placebo                                                                                                                                                                                                                                                                                                                                                                      
   Rui et al[@b83-ndt-12-113]                                                         Int    RCT                                 DB                                                                                                             31.1, 32.3                                                               40.7           Effectiveness, efficacy, safety          Relapse                     Relapse, PANSS, CGI-S, TEAEs
  Paliperidone ER compared with others                                                                                                                                                                                                                                                                                                                                                                       
   Paliperidone ER compared with paliperidone ER + magnesium valproate                                                                                                                                                                                                                                                                                                                                       
    Liu et al^65^                                                                     CC     RCT                                 NR      Blinding                                                                                               36.0                                                                     76.1           Efficacy, safety                         PANSS                       PANSS, TESS
   Paliperidone ER compared with typical antipsychotics and atypical antipsychotics                                                                                                                                                                                                                                                                                                                          
    Liu et al[@b85-ndt-12-113]                                                        CC     RCT                                 NR      Blinding, noncompleters excluded, concomitant antipsychotics                                           33.91, 33.77, 34.04                                                      52.0           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, TESS
   Paliperidone ER compared with paliperidone ER + aripiprazole                                                                                                                                                                                                                                                                                                                                              
    Liang et al^66^                                                                   CC     RCT                                 DB      Noncompleters excluded                                                                                 30.8, 30.3                                                               37.5           Efficacy, safety                         PANSS                       PANSS, AIMS, BARNES, UKU, prolactin
   Paliperidone ER compared with paliperidone ER + escitalopram                                                                                                                                                                                                                                                                                                                                              
    Yan et al[@b88-ndt-12-113]                                                        CC     RCT                                 NR      Blinding                                                                                               39.6, 38.4                                                               51.2           Efficacy, effectiveness, safety          WAIS, WCST                  PANSS, WAIS, WCST, TESS
   Different dose groups of paliperidone ER                                                                                                                                                                                                                                                                                                                                                                  
    Luo et al^67^                                                                     CC     RCT                                 NR      Blinding                                                                                               18--62                                                                   52.5           Efficacy, safety                         PANSS                       PANSS, TESS, metabolic measures
    Huang et al^69^                                                                   Int    Single-arm study                    OL      Observer expectation                                                                                   40.3                                                                     54.6           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, social function score, adverse events
    Tsai et al^76^                                                                    Int    Single-arm study                    NR      Blinding                                                                                               NR                                                                       NR             Effectiveness                            DAI-10                      DAI-10, CGI-S, PSP
    Shi et al[@b89-ndt-12-113]                                                        Int    Single-arm study                    OL      Observer expectation                                                                                   27.6                                                                     48.9           Efficacy, effectiveness, safety          PSP, MATRICS                PSP, MATRICS, PANSS, CGI-S, SAS, BARS, adverse events
    Si et al^70^                                                                      Int    Single-arm study                    OL      Observer expectation, noncompleters excluded                               First-episode               30.0                                                                     50.0           Efficacy, effectiveness, safety          PSP                         PSP, CGI-S, PANSS
    Tang^77^                                                                          Int    Single-arm study                    OL      Observer expectation                                                                                   40.1                                                                     46.1           Efficacy                                 PANSS                       PANSS
    Yang et al^71^                                                                    Int    Single-arm study                    OL      Observer expectation                                                                                                                                                                           Efficacy, effectiveness                  PANSS, PSP                  PANSS, PSP
    Wang et al^72^                                                                    CC     Single-arm study                    NR      Blinding, noncompleters excluded                                                                       18--40                                                                   69.2           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, MSQ, adverse events
    Li et al^78^                                                                      CC     Single-arm study                    NR      Blinding, concomitant antipsychotic                                        Adolescent                  14.4                                                                     43.6           Efficacy, safety                         PANSS                       PANSS, TESS, laboratory examination, prolactin
    Wu et al^79^                                                                      CC     Single-arm study                    OL      Observer expectation, noncompleters excluded                                                           36.65                                                                    35.4           Efficacy, safety                         PANSS, metabolic measures   PANSS, tolerability, metabolic measures
    Zhou et al^73^                                                                    CC     Single-arm study                    NR      Blinding                                                                                               28.7                                                                     47.2           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, metabolic measures, UKU, prolactin
    Chen et al[@b90-ndt-12-113]                                                       CC     Single-arm study                    OL      Observer expectation                                                                                   29.9                                                                     49.0           Effectiveness                            HVLT                        HVLT, BVMT-R, WAIS-III, WMS-III, Stroop, Digit Symbol-Coding, PASAT
    Sun et al^74^                                                                     CC     Single-arm study                    NR      Blinding, noncompleters excluded                                           First-episode, adolescent   13.5                                                                     54.1           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, MSQ, TESS, metabolic measures
    Zhang et al[@b91-ndt-12-113]                                                      CC     Single-arm study                    NR      Blinding, noncompleters excluded                                                                       35.89                                                                    45.2           Effectiveness                            WCST                        WCST, Stroop, TOH
    Lv et al^80^                                                                      CC     Single-arm study                    OL      Observer expectation, noncompleters excluded                                                           39.03                                                                    46.7           Efficacy, safety                         Metabolic measures          Metabolic measures, PANSS, CGI-S, adverse events
    Wang et al[@b98-ndt-12-113]                                                       CC     Single-arm study                    NR      Blinding                                                                                               22.87                                                                    43.5           Efficacy, effectiveness, safety          PANSS, prolactin            PANSS, PSP, adverse events, prolactin
    Zhang et al^75^                                                                   CC     Single-arm study                    OL      Observer expectation, noncompleters excluded                                                           31                                                                       49.5           Efficacy, effectiveness, safety          PANSS                       PANSS, CGI-S, PSP, ESRS, metabolic measures, prolactin
    Liu et al^81^                                                                     CC     Single-arm study                    NR      Blinding                                                                                               40                                                                       53.8           Efficacy                                 PANSS                       PANSS
    Xiong et al[@b130-ndt-12-113]                                                     CC     Observational study                         Noncompleters excluded                                                                                 28.6, 29.2                                                               58.7           Efficacy, safety                         PANSS                       PANSS, TESS
    Si et al^82^                                                                      Int    Pharmacokinetic study               NR      Blinding                                                                   Healthy                     19--35                                                                   54.2           Pharmacokinetics, safety, tolerability   Pharmacokinetics            Pharmacokinetics
  Paliperidone ER compared with paliperidone palmitate                                                                                                                                                                                                                                                                                                                                                       
   Jiang et al^68^                                                                    CC     RCT                                 NR      Blinding                                                                                               32.7, 34.1                                                               53.6           Efficacy, effectiveness, safety          PANSS                       PANSS, TESS, PSP, MSQ
  **Paliperidone palmitate**                                                                                                                                                                                                                                                                                                                                                                                 
  Paliperidone palmitate compared with risperidone                                                                                                                                                                                                                                                                                                                                                           
   Li et al[@b104-ndt-12-113]                                                         Int    RCT                                 OL      Observer expectation                                                                                   31.5, 32.0                                                               32.8           Efficacy, effectiveness, safety          PANSS, PSP, CGI-S           PANSS, PSP, CGI-S, TEAEs
   Ma et al[@b106-ndt-12-113]                                                         CC     RCT                                 OL      Observer expectation, noncompleters excluded                               Adolescent                  16.05, 15.57                                                             51.0           Efficacy, effectiveness, safety          PANSS                       PANSS, PSP, CGI-S, adverse events
   Yi et al[@b107-ndt-12-113]                                                         CC     RCT                                 OL      Observer expectation, noncompleters excluded                                                           31.5, 35.5                                                               42.6           Efficacy, safety                         PANSS                       PANSS, TESS
  Paliperidone palmitate compared with placebo                                                                                                                                                                                                                                                                                                                                                               
   Wakamatsu et al[@b105-ndt-12-113]                                                  Int    RCT                                 DB                                                                                                             45                                                                                      Efficacy, safety                         PANSS                       PANSS, CGI-S, TEAEs
   Zhang et al[@b109-ndt-12-113]                                                      Int    Single-arm study                    OL      Observer expectation                                                       Recent-onset                28.7                                                                     65.5           Efficacy, effectiveness, safety          PANSS                       PANSS, CGI-SCH, MSQ, hospitalization
   Miao et al[@b110-ndt-12-113]                                                       CC     Single-arm study                    OL      Observer expectation, noncompleters excluded, concomitant antipsychotics                               33.2                                                                     39.7           Efficacy, safety                         PANSS                       PANSS, CGI-S, TESS
   Bressington et al[@b108-ndt-12-113]                                                Int    Retrospective observational study           Retrospective                                                                                          40.86                                                                    71.2           Effectiveness                            Hospitalization rate        Hospitalization rate
   Si et al[@b100-ndt-12-113]                                                         Int    Pharmacokinetic study               OL      Observer expectation                                                                                   53                                                                       76.6           Pharmacokinetics, efficacy               Pharmacokinetics            Pharmacokinetics, PANSS, CGI-S
   Li et al[@b101-ndt-12-113]                                                         CC     Pharmacokinetic study               NR      Blinding, noncompleters excluded                                                                       25.44                                                                    44.4           Pharmacokinetics, efficacy, safety       Pharmacokinetics, PANSS     Pharmacokinetics, PANSS, adverse events, laboratory examination

**Note:**

Where two ages appear in this column, they indicate ages for the experimental group and for the comparison group, respectively.

**Abbreviations:** AIMS, Abnormal Involuntary Movement Scale; BARS/BARNES, the Barnes Akathisia Rating Scale-revised; BPRS, Brief Psychiatric Rating Scale; BVMT-R, Wisconsin Brief Visuospatial Memory Tests; CC, Chinese core (journal type); CGI, Clinical Global Impression; CGI-S, Clinical Global Impression-Severity; CGI-SCH, Clinical Global Impression of Schizophrenia; CPT, Continuous Performance Task; CT, Number Cancellation Test; DAI-10, The Drug Attitude Inventory; DB, double-blind; ER, extended-release; ESRS, Extrapyramidal Syndrome Rating Scale; GQOLI-74, The Overall Quality of Life Rating Scale; HVLT, Hopkins Verbal Learning Test-Revised; Int, international (journal type); MATRICS, Measurement and Treatment Research to Improve Cognition in Schizophrenia; MSQ, Medication Satisfaction Questionnaire; NR, not reported; OL, open-label; PANSS, Positive and Negative Symptom Scale; PASAT, Paced Auditory Serial Addition Task; PSP, Personal and Social Functioning Scale; RCT, randomized controlled trial; SAPS, scale for assessment of positive symptoms; SAS, Simpson Angus Scale; SDSS, Social Disability Screening Schedule; SF36, Short Form-36; Stroop, Stroop Color and Word Test; TEAEs, treatment-emergent adverse events; TESS, Treatment-Emergent Symptom Scale; TOH, tower of Hanoi; UKU, Udvalg for Kliniske Undersogelser Side Effect Rating Scale; VAS, Visual Analog Scale; WAIS, Wechsler Adult Intelligence Scale; WAIS-III, Symbol Search Test; WCST, Wisconsin Card Sorting Test; WHOQOL, World Health Organization Quality of Life; WMS-R, Wechsler Memory Scale-Revised; WMS-III, Spatial Span subtest of Wechsler Memory Scale-III.
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###### 

Efficacy of paliperidone ER in comparative studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                     Blind   Treatment arms                          Dose (mg/d)   Number of patients (enrolled)   Duration (weeks)   Mean change (% reduction versus baseline)   *P*-value                                                     Response rate (%)                                               Remarks                
  ------------------------------ ------- --------------------------------------- ------------- ------------------------------- ------------------ ------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------- ---------- ----------- -----------------------------------------------------------------------------------
  **Risperidone**                                                                                                                                                                                                                                                                                                                                  

  Liu et al[@b11-ndt-12-113]     OL      Paliperidone ER                         6.60          3--9                            25                 8                                                                                                         −38.80[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (42.23)     NS         80%^A^      

                                         Risperidone                             4.40          1--6                            25                                                                                                                           −36.80[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (40.51)                76%^A^      

  Li et al[@b17-ndt-12-113]      NR      Paliperidone ER                                       6--12                           48                 12                                                                                                        −34.7[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (36.37)        \<0.05                 

                                         Risperidone                                           2--6                            62                                                                                                                           −26.4[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (27.16)                               

  Su et al[@b46-ndt-12-113]      OL      Paliperidone ER                         6.3           3--12                           47                 12                                                                                                        −41.6[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (48.54)        \<0.05     64%^B^      

                                         Risperidone                             3.8           1--6                            45                                                                                                                           −32.8[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (38.41)                   60%^B^      

  Ren et al[@b47-ndt-12-113]     NR      Paliperidone ER                                       3--9                            76                 4                                                                                                         −48.73[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (54.53)       \<0.05                 

                                         Risperidone                                           1--6                            79                                                                                                                           −39.15[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (44.44)                              

  Zhou et al[@b48-ndt-12-113]    NR      Paliperidone ER                                       3--12                           38                 8                                                                                                         −59.77[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (57.38)     NS         82.9%^A^    

                                         Risperidone                                           2--6                            38                                                                                                                           −43.23[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (41.69)                86.5%^A^    

  Na et al[@b20-ndt-12-113]      OL      Paliperidone ER                                       6                               40                 8                                                                                                         −39.7[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (47.26)      NS         62.5%^B^    

                                         Risperidone                                           1--4                            40                                                                                                                           −41.3[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (48.88)                 67.5%^B^    

  Li et al[@b49-ndt-12-113]      NR      Paliperidone ER                         8.32          3--12                           14                 6                                                                                                         −37.86[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (43.52)   NS                     

                                         Risperidone                             5.86          1--6                            20                                                                                                                           −36.60[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (42.29)                          

  Zhang et al[@b50-ndt-12-113]   NR      Paliperidone ER                         9             3--12                           47                 6                                                                                                         −28.2[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (34.60)      NS         70%^B^      

                                         Risperidone                             5             2--6                            47                                                                                                                           −27.4[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (33.91)                 66%^B^      

  Yuan et al[@b51-ndt-12-113]    NR      Paliperidone ER                         8.9           3--12                           45                 6                                                                                                         −38.42[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (41.10)     NS                     

                                         Risperidone                             4.9           1--6                            45                                                                                                                           −37.46[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (39.49)                            

  Li et al[@b52-ndt-12-113]      OL      Paliperidone ER                         6.67          3--9                            40                 8                                                                                                         −38.37[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (44.45)     NS         67.5%^C^    

                                         Risperidone                             4.32          1--6                            40                                                                                                                           −36.88[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (42.90)                65%^C^      

  Deng et al[@b53-ndt-12-113]    OL      Paliperidone ER                         8.76          6--12                           38                 6                                           −28.37 (57.52)                                                                                                                NS         94.74%^D^   

                                         Risperidone                             5.42          4--8                            38                                                             −29.73 (58.48)                                                                                                                           92.11%^D^   

  Liu et al[@b54-ndt-12-113]     DB      Paliperidone ER                         5.8                                           45                 8                                                                                                         −44.26 (54.19)                                                  \<0.05                 

                                         Risperidone                             4.2                                           45                                                                                                                           −41.47 (51.31)                                                                         

  Wang et al[@b18-ndt-12-113]    OL      Paliperidone ER                                       3--12                           41                 12                                                                                                        −43.3[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (46.31)      \<0.05                 

                                         Risperidone                                           1--8                            40                                                                                                                           −23.2 (25.27)                                                                          

  Xiong et al[@b55-ndt-12-113]           Paliperidone ER                         5.49          3--9                            127                8                                                                                                         −28.4 (42.01)                                                   \<0.05     80.3%^E^    Observational study

                                         Risperidone                                           1--4                            139                                                                                                                          −24.0 (35.98)                                                              74.8%^E^    

  **Olanzapine**                                                                                                                                                                                                                                                                                                                                   

  Hu et al[@b21-ndt-12-113]      OL      Paliperidone ER                         7.55                                          40                 12                                                                                                        −20.33[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (25.57)   NS                     

                                         Olanzapine                              15.87                                         40                                                                                                                           −23.39[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (31.63)                          

  Zhu et al[@b24-ndt-12-113]     NR      Paliperidone ER                         10.1          3--12                           15                 12                                                                                                        −30.87[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (34.62)       NS         73%^A^      

                                         Olanzapine                              14.6          5--20                           15                                                                                                                           −26.25[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (29.42)                  67%^A^      

  Xie et al[@b56-ndt-12-113]     OL      Paliperidone ER                         6.4           3--12                           40                 12                                                                                                        −35.60[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (41.21)     NS         85.7%^A^    

                                         Olanzapine                              17.5          2.5--20                         40                                                                                                                           −38.59[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (43.45)                87.5%^A^    

  Ma et al[@b57-ndt-12-113]      NR      Paliperidone ER                         7.6           3--12                           80                 8                                           −28.5[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (55.4)                                                                   NS         68.75%^D^   

                                         Olanzapine                              17.8          10--20                          76                                                             −28.9[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (57.1)                                                                              65.78%^D^   

  Cao et al[@b58-ndt-12-113]     NR      Paliperidone ER                                       3--12                           30                 12                                                                                                        −45.0[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (53.9)       NS         93.3%^A^    

                                         Olanzapine                                            5--20                           32                                                                                                                           −50.2[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (58.7)                  90.6%^A^    

  Su et al[@b59-ndt-12-113]      NR      Paliperidone ER                         6.25          3--9                            32                 8                                                                                                         −38.60 (58.95)                                                  NS         78.13%^F^   

                                         Olanzapine                              10            5--10                           34                                                                                                                           −39.12 (59.04)                                                             76.47%^F^   

  Liang[@b60-ndt-12-113]         OL      Paliperidone ER                                       3--12                           39                 6                                                                                                         −57.53[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (59.26)       \<0.05     97.37%^A^   

                                         Olanzapine                                            5--20                           39                                                                                                                           −53.26[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (55.16)                  78.95%^A^   

  Guo et al[@b61-ndt-12-113]     NR      Paliperidone ER                                       3--12                           30                 8                                                                                                         −40.8[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (49.76)      \<0.05                 

                                         Olanzapine                                            5--20                           30                                                                                                                           −31.4[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (40.99)                             

  Zhang et al[@b22-ndt-12-113]   DB      Paliperidone ER                                       3--12                           143                6                                                                                                         −32.3[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (38.8)     NS         71%^G^      

                                         Olanzapine                                            5--15                           145                                                                                                                          −34.1[\*\*\*](#tfn4-ndt-12-113){ref-type="table-fn"} (39.8)                69.1%^G^    

  **Aripiprazole**                                                                                                                                                                                                                                                                                                                                 

  Zhang et al[@b9-ndt-12-113]    OL      Paliperidone ER                         6.4                                           81                 52                                                                                                        −32.2[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (36.96)        \<0.05                 

                                         Aripiprazole                            14.5                                          90                                                                                                                           −21.2[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (23.61)                               

                                         Ziprasidone                             65.3                                          83                                                                                                                           −18.7[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (21.25)                               

  Xie et al[@b62-ndt-12-113]     NR      Paliperidone ER                         9             3--12                           34                 12                                                                                                        −38.6[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (42.97)      NS         72%^B^      

                                         Aripiprazole                            15            2.5--20                         34                                                                                                                           −35.5[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (40.62)                 68%^B^      

  Zhou et al[@b63-ndt-12-113]    NR      Paliperidone ER                                       3--12                           38                 8                                                                                                         −60.0[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (57.58)        NS         86.8%^H^    

                                         Aripiprazole                                          5--20                           40                                                                                                                           −58.4[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (56.43)                   85%^H^      

  **Clozapine**                                                                                                                                                                                                                                                                                                                                    

  Luo et al[@b12-ndt-12-113]     NR      Paliperidone ER                         7.6           3--12                           30                 12                                                                                                        −49.4[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (52.83)      NS                     

                                         Clozapine                               278.7         200--500                        30                                                                                                                           −44.6[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (48.38)                             

  Liu et al[@b64-ndt-12-113]     OL      Paliperidone ER                         6.12          3--9                            25                 12                                                                                                        −32.88[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (39.01)     NS         72%^I^      

                                         Clozapine                               498.00        25--600                         25                                                                                                                           −31.96[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (37.56)                68%^I^      

  **Ziprasidone**                                                                                                                                                                                                                                                                                                                                  

  Zhang et al[@b9-ndt-12-113]    OL      Paliperidone ER                         6.4                                           81                 52                                                                                                        −32.2[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (36.96)        \<0.05                 

                                         Aripiprazole                            14.5                                          90                                                                                                                           −21.2[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (23.61)                               

                                         Ziprasidone                             65.3                                          83                                                                                                                           −18.7[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (21.25)                               

  He et al[@b19-ndt-12-113]      DB      Paliperidone ER                         6.2           3--12                           70                 8                                                                                                         −49.24[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (49.48)     \<0.05     90%^A^      

                                         Ziprasidone                             80.8          40--160                         70                                                                                                                           −44.13[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (44.72)                74.3%^A^    

  **Placebo**                                                                                                                                                                                                                                                                                                                                      

  Rui et al[@b8-ndt-12-113]      DB      Paliperidone ER                         9.5           3--12                           64                 56                                                                                                        16.9 (32.82)                                                    \<0.0001               Patients had received 14 days of treatment before attaining baseline PANSS scores

                                         Placebo                                                                               71                                                                                                                           2 (3.75)                                                                               

  **Others**                                                                                                                                                                                                                                                                                                                                       

  Liu et al[@b65-ndt-12-113]     NR      Paliperidone ER + magnesium valproate                 6--9                            23                 12                                                                                                        −56.7[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (53.69)        \<0.05                 

                                                                                               250--900                                                                                                                                                                                                                                            

                                         Paliperidone ER                                       6--9                            23                                                                                                                           −37.3[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (35.62)                               

  Liu et al[@b10-ndt-12-113]     NR      Paliperidone ER                                       3--12                           58                 24                                                                                                        −51.47[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (60.61)     \<0.05                 

                                         Typical antipsychotics                                                                57                                                                                                                           −43.27[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (50.79)                            

                                         Atypical antipsychotics                                                               60                                                                                                                           −48.62[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (57.42)                            

  Liang et al[@b66-ndt-12-113]   DB      Paliperidone ER + aripiprazole          6.0           3--12\                          20                 4                                                                                                         −12.9 (17.74)                                                   \<0.05                 
                                                                                               10                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                   

                                         Paliperidone ER                         9.6           3--12                           21                                                                                                                           −28.9 (36.44)                                                                          

  Yan et al[@b13-ndt-12-113]     NR      Paliperidone ER + escitalopram          6.2\          3--9\                           42                 12                                                                                                        −16.13[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (22.13)       \<0.05     85.7%^A^    
                                                                                 15.2          10--20                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                   

                                         Paliperidone ER                         6.5           3--9                            42                                                                                                                           −12.11[\*](#tfn2-ndt-12-113){ref-type="table-fn"} (16.49)                  64.3%^A^    

  Luo et al[@b67-ndt-12-113]     NR      3 mg paliperidone ER                    3             3                               20                 8                                                                                                         −23.41[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (26.42)     \<0.05     70%^J^      

                                         6 mg paliperidone ER                    6             6                               20                                                                                                                           −30.58[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (34.34)                80%^J^      

                                         9 mg paliperidone ER                    9             9                               20                                                                                                                           −36.54[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (41.07)                85%^J^      

                                         12 mg paliperidone ER                   12            12                              20                                                                                                                           −36.82[\*\*](#tfn3-ndt-12-113){ref-type="table-fn"} (41.66)                85%^J^      

  **Paliperidone palmitate**                                                                                                                                                                                                                                                                                                                       

  Jiang et al[@b68-ndt-12-113]   OL      Paliperidone ER\                                      3--12\                          40\                13                                                                                                        −8.0 (15.15)\                                                   NS                     Patients had received 6 weeks of treatment before attaining baseline PANSS scores
                                         Paliperidone palmitate                                75--150 (mg/month)              40                                                                                                                           −10.2 (18.92)                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Response rate definition -- A: response = PANSS reduction ≥25%; B: response = (PANSS in baseline − PANSS in visit point)/(PANSS in baseline -- 30)·100%\$50%; C: response = relief + improvement; D: response = (BPRS in baseline -- BPRS in visit point)/(BPRS in baseline -- 18)·100%≥50%; E: response = PANSS reduction \$20%; F: response = BPRS reduction \$80%; G: response = PANSS reduction \$50%; H: response = PANSS reduction \$30%; I: response = (PANSS in baseline -- PANSS in visit point)/(PANSS in baseline -- 30)·100%≥25%; J: response = not reported.

*P*\<0.05;

*P*\<0.01;

*P*\<0.001.

**Abbreviations:** BPRS, Brief Psychiatric Rating Scale; DB, double-blind; ER, extended-release; NR, not reported; NS, not significant; OL, open-label; PANSS, Positive and Negative Syndrome Scale.

###### 

PANSS total score in week 1--2 in RCTs

  References                     Treatment arms    PANSS total score   Dose titration                                                                                     Remarks                                                                                                                                                                                                                                                                             
  ------------------------------ ----------------- ------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------
  Li et al[@b17-ndt-12-113]      Paliperidone ER   95.4                88.0[\*](#tfn7-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}        83.3[\*](#tfn7-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}        6 mg/d was recommended; 9--12 mg/d was used when necessary                                                                                                                       
                                 Risperidone       97.2                92.9                                                                                               88.3[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                    2 mg/d was recommended; 4--6 mg/d was used when necessary                                                                                                                        
  Na et al[@b20-ndt-12-113]      Paliperidone ER   84.0                                                                                                                   65.1[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}      6 mg/d                                                                                                                                                                           
                                 Risperidone       84.5                                                                                                                   79.0[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                    Started with 1 mg/d; increased to 4 mg/d in 1 week                                                                                                                               
  Li et al[@b49-ndt-12-113]      Paliperidone ER   87.00               69.43[\*\*\*](#tfn9-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}   58.78[\*\*\*](#tfn9-ndt-12-113){ref-type="table-fn"}                                               Started with 3 mg/d; 9--12 mg/d was used when necessary. The average dose was 8.32 mg/d                                                                                          
                                 Risperidone       86.55               81.70                                                                                              60.20[\*\*\*](#tfn9-ndt-12-113){ref-type="table-fn"}                                               Started with 1 mg/d; 4--6 mg/d was used when necessary. The average dose was 5.86 mg/d                                                                                           
  Zhang et al[@b50-ndt-12-113]   Paliperidone ER   81.5                                                                                                                   64.7[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[++](#tfn11-ndt-12-113){ref-type="table-fn"}     Started with 3 mg/d; an additional 3 mg/d was added every 1--2 weeks; final dose ranged from 3 to 12 mg/d. The average dose was 9 mg/d                                           
                                 Risperidone       80.8                                                                                                                   75.1[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                  Started with 2 mg/d; an additional 2 mg/d was added every 1--3 days; dose was increased to 4--6 mg/d in 2 weeks. The average dose is 5 mg/d                                      
  Yuan et al[@b51-ndt-12-113]    Paliperidone ER   93.49               80.51[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}     68.84[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}     Started with 3 mg/d; increased to 6--12 mg/d in 2 weeks according to clinical judgment. The average dose was 8.9 mg/d                                                            
                                 Risperidone       94.86               86.50[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 75.86[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 Started with 1 mg/d; increased to 3--6 mg/d in 2 weeks according to clinical judgment. The average dose was 4.9 mg/d                                                             
  Li et al[@b52-ndt-12-113]      Paliperidone ER   86.32                                                                                                                  67.02[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}     Started with 3 mg/d; increased to 6 mg/d in 1 week; a maximum of 9 mg/d was used according to clinical judgment. The average dose was 6.67 mg/d                                  
                                 Risperidone       85.96                                                                                                                  73.04[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 Started with 1 mg/d; increased to 4 mg/d in 1 week; a maximum of 6 mg was used according to clinical judgment. The average dose was 4.32 mg/d                                    
  Liu et al[@b54-ndt-12-113]     Paliperidone ER   81.68                                                                                                                  57.91[\*\*\*](#tfn9-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}   Started with 6 mg/d; adjusted individual dose after 2 weeks according to clinical judgment. The average dose was 5.8 mg/d                                                        
                                 Risperidone       80.82                                                                                                                  65.41[\*\*\*](#tfn9-ndt-12-113){ref-type="table-fn"}                                               Started with 2 mg/d; adjusted individual dose in 2 weeks according to clinical judgment. The average dose was 4.2 mg/d                                                           
  Zhu et al[@b24-ndt-12-113]     Paliperidone ER   89.16               82.58[+](#tfn10-ndt-12-113){ref-type="table-fn"}                                                   76.79[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 Started with 3 mg/d; increased to 6--12 mg/d (average 9.5) in 1 week                                                                                                             
                                 Olanzapine        89.23               83.69                                                                                              80.62[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 Started with 5 mg/d; increased to 10--20 mg/d (average 14.6) in 1 week                                                                                                           
  Xie et al[@b56-ndt-12-113]     Paliperidone ER   88.82                                                                                                                  68.33[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}     Started with 3 mg/d; another 3 mg/d was added every 1--2 weeks; final dose ranged from 3 to 12 mg/d according to clinical judgment. The average dose was 6.4 mg/d                
                                 Olanzapine        86.39                                                                                                                  76.83[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                 Started with 2.5 mg/d; an additional 2.5--5 mg/d was added every 5--7 days; final dose ranged from 5 to 20 mg/d according to clinical judgment. The average dose was 17.5 mg/d   
  Ma et al[@b57-ndt-12-113]      Paliperidone ER   51.4                43.8[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}      39.7[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                  Started with 3 mg/d; increased to 6--12 mg/d after 1 week. The average dose was 7.6 mg/d                                                                                         BPRS
                                 Olanzapine        50.6                48.2                                                                                               40.4[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                  Started with 10 mg/d; increased to 15--20 mg/d after 1 week. The average dose was 17.8 mg/d                                                                                      
  Cao et al[@b58-ndt-12-113]     Paliperidone ER   85.4                77.1[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                    73.8[\*\*](#tfn8-ndt-12-113){ref-type="table-fn"}                                                  Started with 3 mg/d; adjusted to 3--12 mg/d in 2 weeks according to clinical judgment                                                                                            
                                 Olanzapine        82.2                80.4                                                                                               75.5[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                    Started with 5 mg/d; adjusted to 5--20 mg/d in 2 weeks according to clinical judgment                                                                                            
  Su et al[@b59-ndt-12-113]      Paliperidone ER   65.48               54.80[\*](#tfn7-ndt-12-113){ref-type="table-fn"},[+](#tfn10-ndt-12-113){ref-type="table-fn"}       40.10[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   Started with 6 mg/d; adjusted to 3--9 mg/d in 1--2 weeks according to clinical judgment. The average dose was 6.25 mg/d                                                          
                                 Olanzapine        66.26               61.35[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   40.74[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   Started with 5 mg/d; increased to 10 mg/d in 1 week                                                                                                                              
  Liang et al[@b60-ndt-12-113]   Paliperidone ER   97.08               67.97[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   55.29[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   Started with 3 mg/d or 6 mg/d for severe cases; increased to 6 or 12 mg/d in 10 days                                                                                             
                                 Olanzapine        96.55               73.11[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   58.45[\*](#tfn7-ndt-12-113){ref-type="table-fn"}                                                   Started with 5 mg/d or 10 mg/d for severe cases; increased to 15 or 20 mg/d in 10 days                                                                                           
  Guo et al[@b61-ndt-12-113]     Paliperidone ER   82                                                                                                                     55.8[+](#tfn10-ndt-12-113){ref-type="table-fn"}                                                    Started with 6 mg/d; increased to 9 or 12 mg/d in 4--7 days. Final dose ranged from 3 to 12 mg/d according to clinical judgment                                                  
                                 Olanzapine        76.6                                                                                                                   63.8                                                                                               Started with 10 or 20 mg/d; adjusted to 5--20 mg/d according to clinical judgment                                                                                                

**Notes:** Versus baseline:

*P*\<0.05;

*P*\<0.01;

*P*\<0.001. Versus comparison group:

*P*\<0.05;

*P*\<0.01.

**Abbreviations:** BPRS, Brief Psychiatric Rating Scale; ER, extended-release; PANSS, Positive and Negative Syndrome Scale; RCTs, randomized controlled trials.

###### 

PSP score of paliperidone ER studies

  References                     Study design   Treatment arms            PSP score   Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ------------------------------ -------------- ------------------------- ----------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------
  Li et al[@b17-ndt-12-113]      RCT            Paliperidone ER           46.8                                                              47.9                                                                                              54.6[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                      60.3[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                             
                                                Risperidone               47.2                                                              48.1                                                                                              52.7[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                      55.1[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                         
  Su et al[@b46-ndt-12-113]      RCT            Paliperidone ER           45.57                                                                                                                                                                                                                                                                                                                                                                   64.46[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 74.32[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                            
                                                Risperidone               44.12                                                                                                                                                                                                                                                                                                                                                                   63.32[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 59.87[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                        
  Ren et al[@b47-ndt-12-113]     RCT            Paliperidone ER           31.77                                                                                                                                                               48.72[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                  
                                                Risperidone               32.54                                                                                                                                                               37.67                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Zhou et al[@b48-ndt-12-113]    RCT            Paliperidone ER           27.98                                                                                                                                                                                                                                                                                                                                                                   52.34[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                           
                                                Risperidone               28.52                                                                                                                                                                                                                                                                                                                                                                   42.06                                                                                                                                                                                                                                                      
  Li et al[@b49-ndt-12-113]      RCT            Paliperidone ER           56.87                                                                                                                                                               69.78[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 78.59[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                
                                                Risperidone               57.35                                                                                                                                                               61.38                                                                                             66.57[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                            
  Yuan et al[@b51-ndt-12-113]    RCT            Paliperidone ER           32.79       38.12[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}   51.67[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}   59.79[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}   65.74[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                              
                                                Risperidone               31.55       35.24[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}   45.05[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               53.29[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               60.10[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                          
  Xie et al[@b56-ndt-12-113]     RCT            Paliperidone ER           32.75                                                                                                                                                                                                                                                                                                                                                                   51.58[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}   68.85[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                         
                                                Olanzapine                31.47                                                                                                                                                                                                                                                                                                                                                                   45.03[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               60.13[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                      
  Liang et al[@b60-ndt-12-113]   RCT            Paliperidone ER           25.00       41.79[\*](#tfn14-ndt-12-113){ref-type="table-fn"}     52.37[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 68.74[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[++](#tfn17-ndt-12-113){ref-type="table-fn"}    77.11[\*](#tfn14-ndt-12-113){ref-type="table-fn"},[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                               
                                                Olanzapine                27.06       40.26[\*](#tfn14-ndt-12-113){ref-type="table-fn"}     51.05[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 62.53[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                 70.05[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                            
  Xie et al[@b62-ndt-12-113]     RCT            Paliperidone ER           32.75                                                                                                                                                                                                                                                                                                                                                                   52.68[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[+](#tfn16-ndt-12-113){ref-type="table-fn"}   69.87[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                         
                                                Aripiprazole              32.47                                                                                                                                                                                                                                                                                                                                                                   46.05[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               61.24[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                      
  Zhou et al[@b63-ndt-12-113]    RCT            Paliperidone ER           45.2                                                                                                                                                                                                                                                                                                                                                                    78.0[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"},[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                                                                                                                            
                                                Aripiprazole              46.5                                                                                                                                                                                                                                                                                                                                                                    55.1                                                                                                                                                                                                                                                       
  Liu et al[@b10-ndt-12-113]     RCT            Paliperidone ER           50.72                                                                                                                                                               66.91[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                   71.89[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                78.87[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}   ++ versus paliperidone ER *P*\<0.01
                                                Typical antipsychotics    51.57                                                                                                                                                               58.25[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                     52.68[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                  52.00[++](#tfn17-ndt-12-113){ref-type="table-fn"}     
                                                Atypical antipsychotics   50.51                                                                                                                                                               58.32[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                     68.30[++](#tfn17-ndt-12-113){ref-type="table-fn"}                                                  70.89[++](#tfn17-ndt-12-113){ref-type="table-fn"}     
  Huang et al[@b69-ndt-12-113]   Single arm     Paliperidone ER           47.07                                                                                                                                                                                                                                                                                                                                                                                                                                                                     56.61[\*](#tfn14-ndt-12-113){ref-type="table-fn"}                                                                                                        
  Shi et al[@b14-ndt-12-113]     Single arm     Paliperidone ER           54.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         73.4[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}    
  Si et al[@b70-ndt-12-113]      Single arm     Paliperidone ER           41.4                                                                                                                                                                66.9                                                                                                                                                                                                75.5[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                         
  Yang et al[@b71-ndt-12-113]    Single arm     Paliperidone ER           47.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                      56.6                                                                                                                                                     
  Wang et al[@b72-ndt-12-113]    Single arm     Paliperidone ER           52.28                                                             64.44[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               70.36[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                            
  Zhou et al[@b73-ndt-12-113]    Single arm     Paliperidone ER           39.5        52.5[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}    62.6[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                70.5[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                  72.6[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                         
  Sun et al[@b74-ndt-12-113]     Single arm     Paliperidone ER           33.57                                                                                                                                                                                                                                                                                                                                                                                                                                                                     58.46[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                71.32[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}   
  Wang et al[@b23-ndt-12-113]    Single arm     Paliperidone ER           51.26       61.13[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}   61.17[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                               69.43[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                 73.52[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                                                                                                                        
  Zhang et al[@b75-ndt-12-113]   Single arm     Paliperidone ER           58.6                                                                                                                                                                                                                                                                                                                                                                    72.4[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                74.5[\*\*](#tfn15-ndt-12-113){ref-type="table-fn"}                                                                                                       

**Notes:** Versus baseline:

*P*\<0.05;

*P*\<0.01. Versus comparison group:

*P*\<0.05;

*P*\<0.01.

**Abbreviations:** ER, extended-release; PSP, Personal and Social Performance Scale; RCT, randomized controlled trial.
